Medical researchers say they are not giving up hope in the battle against Alzheimer’s disease after data revealed that a much-anticipated drug failed to slow the progression of the disease.
Baxter International announced last week it would discontinue research on its experimental drug Gammagard, after tests showed it did not stabilize or slow dementia in patients who received 18 months worth of the blood-product compound.
The Alois Alzheimer Foundation 